Stock Events

Stock Events

Chimeric Therapeutics Limited 

$0
4
-$0-0% Monday 20:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
30,000
Avg. Volume
0
Mkt Cap
4.11M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebExpected
Q2 2023
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.03
-0.02
-0.01
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-260.64%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
5.22MRevenue
-13.61MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CHMMF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing and CAR T-cell therapies, a direct competitor in gene-based cancer treatments.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics focuses on allogeneic CAR T therapies for cancers, directly competing with Chimeric's technologies.
Precigen
PGEN
Mkt Cap1.46B
Precigen operates in the synthetic biology field developing CAR T therapies, competing in the same innovative cancer treatment sector.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR T-cell therapies, directly competing in the oncology segment.
Novartis
NVS
Mkt Cap237.61B
Novartis is a major player in the healthcare sector with successful commercial CAR T-cell therapies, competing on a global scale.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics engages in genomic medicine, including gene-edited cell therapies for cancer, competing in the advanced therapy sector.

About

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Show more...
CEO
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
Country
AU
ISIN
AU0000121576

Listings

AU
AU
CHM.AU
OTC Link
US
CHMMF

0 Comments

Share your thoughts

FAQ

What is Chimeric Therapeutics Limited stock price today?▼
The current price of CHMMF is $0 USD — it has decreased by -0% in the past 24 hours. Watch Chimeric Therapeutics Limited stock price performance more closely on the chart.
What is Chimeric Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Chimeric Therapeutics Limited stocks are traded under the ticker CHMMF.
Is Chimeric Therapeutics Limited stock price growing?▼
CHMMF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Chimeric Therapeutics Limited has showed a +0% increase.
What is Chimeric Therapeutics Limited market cap?▼
Today Chimeric Therapeutics Limited has the market capitalization of 4.11M
When is the next Chimeric Therapeutics Limited earnings date?▼
Chimeric Therapeutics Limited is going to release the next earnings report on August 28, 2026.
What is Chimeric Therapeutics Limited revenue for the last year?▼
Chimeric Therapeutics Limited revenue for the last year amounts to 5.22M USD.
What is Chimeric Therapeutics Limited net income for the last year?▼
CHMMF net income for the last year is -13.61M USD.
In which sector is Chimeric Therapeutics Limited located?▼
Chimeric Therapeutics Limited operates in the Health Care sector.
When did Chimeric Therapeutics Limited complete a stock split?▼
Chimeric Therapeutics Limited has not had any recent stock splits.
Where is Chimeric Therapeutics Limited headquartered?▼
Chimeric Therapeutics Limited is headquartered in Carlton, AU.